Rev MlO is a ^ans-dominant negative inhibitor of HIV replication. Hence, stable transduction of CD4"'" T cells with Rev MlO represents a novel gene therapy aimed at inhibiting HIV replication within these cells, thereby slowing the progression of AIDS. However, the immune system may recognize Rev MlO as foreign and target transduced cells for elimination. In the current study, mice were genetically immunized with a plasmid encoding Rev MlO, to (1) identify immune parameters that may be induced by Rev MlO gene transfer, (2) determine the impact of repeated introduction of the Rev MlO-encoding plasmid on the immune response to the transgene product, and (3) determine if cotransfection with a plasmid encoding TGF/31 would suppress the response. Kinetic studies revealed that Rev-specific IL-2-producing helper T lymphocytes (HTLs) appeared following the second genetic immunization, peaked after the third, and persisted at peak levels for at least 6 weeks. Rev-specific HTLs were CD4"'", and the development of these cells was ablated by cotransfection with TGF/31. Other cytokines were not readily detectable when immune splenocytes were restimulated with Rev in vitro, and Rev-specific IgG antibodies were not present in the sera of these mice. To our knowledge, this represents the first report that genetic immunization with Rev MlO induces an immune response that is dominated by IL-2-producing HTLs. Further, this study demonstrates the potential utility of introducing immunosuppressive genes as a means to control the immune response to foreign transgene products.
INTRODUCTION transfected tissues. The majority of studies that address these issues have focused on cytotoxic T lymphocyte (CTL) ''t ihe transfer of antiviral genes represents a novel stratand antibody responses induced by gene transfer. However, X egy aimed at inhibiting human immunodeficiency virus the IL-2-producing helper T lymphocyte (HTL) represents (HIV) replication and the subsequent decay of the immune sysa critical regulatory cell that likely influences the inductive tem in HIV-infected individuals. The nuclear protein Rev serves phase of the immune response following gene transfer. The as a likely target for this gene transfer-based modality, in that current study employed limiting dilution analysis (LDA) Rev is essential for viral replication. Rev acts in concert with techniques to characterize the development of IL-2-pro-host cell factors to facilitate the export of unspliced viral ducing HTLs induced hy genetic vaccination with a plasmid mRNAs into the cytoplasm, and is thought to be important in 'Department of Surgery, ^Department of Intemal Medicine, ^Department of Biological Chemistry, Howard Hughes Medical Institute,'* and ^Department of Microbiology and Immunology, University of Michigan Medical Center, Ann Arbor, MI 48109. regulating virus latency (CuUen etal, 1988; Malim etal, 1991; Liu et al, 1994) . Introduction of two point mutations in a highly conserved region of Rev gives rise to a defective protein. Rev MlO, which acts as a fran^-dominant negative inhibitor of wildtype Rev (Sodroski e/a/., 1986; Malim era/., 1989 Malim era/., ,1992 Bevec et al, 1992; Bahner et al, 1993) . Importantiy, transfection of human T cells with Rev MlO inhibits viral replication following challenge with HIV in vitro (Malim et al, 1992; Bevec et al, 1992; Woffendin et al, 1994) .
The immune system has an exquisite ability to discriminate self from non-self and mount a variety of effector mechanisms aimed at eliminating non-self Since many gene transfer protocols introduce foreign transgenes, this aspect of the immune system may or may not be beneficial, depending on the intended outcome of the therapy. For example, Tang et al. (1992) were the first to demonstrate the utility of gene transfer for deliberate immunization to a transgene product. This approach has since proved useful in generating immune responses to infectious disease agents and tumors (Robinson et al, 1993; Yankauckas et al, 1993; Raz et al, 1994; Davis et al, 1995; Michel et al, 1995; Mor et al, 1995; Huygen et al, 1996; Schirmbeck et al, 1996) . However, the success of gene transfer strategies designed as replacement therapies to correct genetic disorders may be compromised by the immune response to the transgene product. Indeed, numerous reports have verified that the immune system represents a major obstacle to the success of in vivo gene replacement therapies (Kay et al, 1994; Blaese et al, 1995; Dwarki et al, 1995; Fang et al, 1995; Kozarsky etal, 1996; Riddell etal, 1996; Tripathy etal, 1996; Hurwitz et al, 1997) . Both conventional and experimental immunosuppressive protocols have been employed in an attempt to control gene transfer-induced immune responses (Fang et al, 1995; Kay et al, 1995; DeMatteo et al, 1996; Yang et ai, 1996) .
Similarly, the success of Rev MlO-based gene therapies aimed at protecting T cells from HIV replication is dependent on the in vivo persistence of Rev MlO-transduced cells. However, Rev MlO represents a foreign protein that may be targeted by the immune system, possibly leading to the elimination of transduced cells. While sequential administrations of Rev MlOtransduced cells may temporarily replace those cells eliminated by the immune system, repeated introduction of the foreign transgene would likely amplify the anti-Rev MlO immune response. The current study was designed to elucidate parameters of the immune response that may be induced by Rev MlO gene transfer, and to assess quantitatively the effects of repeated gene transfer on the anti-Rev immune response. We have previously reported that the emergence of antigen-specific interleukin 2 (IL-2)-producing helper T lymphocytes (HTLs) reflects in vivo immune responses that culminate in inflammation and tissue damage (Bishop et al, 1992; DeBruyne et ai, 1993 DeBruyne et ai, , 1995 . Hence, we employed limiting dilution analysis (LDA) techniques to quantify Rev-specific HTLs, and assessed the development of Rev-specific antibodies following multiple intramuscular injections with a plasmid encoding Rev MlO. In addition, cotransfer of a plasmid encoding transforming growth factor /31 (TGF/31) was employed as an immunosuppressive modality aimed at ablating the anti-Rev HTL response. The data reveal that HTLs, but not antibodies, are induced by genetic vaccination with Rev MlO. Further, these data suggest that coadministration of an immunosuppressive gene may enhance the efficacy of in vivo gene transfer by inhibiting the HTL response to the transgene product.
MATERIALS AND METHODS

Mice
Female BALB/c and C57BL/6 mice between 6 and 12 weeks of age were obtained from Charles River Laboratories (Raleigh, NC).
Medium
The culmre medium used in these studies was Dulbecco's modified Eagle's medium (DMEM) supplemented with 1.6 mM L-glutamine, 0.27 mM L-asparagine, 1.4 mM L-arginine-HCl, 14 mM folic acid, 10 mM HEPES buffer, 1.0 mM sodium pyruvate, penicillin/streptomycin (100 units/ml), 2% heat-inactivated fetal calf serum (FCS) (all obtained from Life Technologies, Grand Island, NY), and 5 X 10"^ M 2-mercaptoethanol (2-ME; Sigma Chemicals, St. Louis, MO).
Rev MlO genetic vaccination
The Rev MlO expression plasmid pCMV Rev MlO was constructed by inserting die Rev MlO cDNA into the Xbal and Pstl sites of pVR1332 T/3. This backbone contains the cytomegalovirus (CMV) enhancer, promoter, and first intron to increase expression, the rabbit j8-globin polyadenylation sequence, and the kanamycin resistance gene. BALB/c or C57BL/6 mice were genetically vaccinated by multiple intramuscular injections with pCMV Rev MlO. Plasmid injections (100 /Ug of DNA total, 50 yug/hind limb) were administered 2 weeks apart, and splenocytes were harvested 10 days following the last plasmid injection. Where indicated, pCMV Rev MlO was admixed with an equal concentration of VR1012 TGF^, which encodes the active form of human TGF/31. The VRI0I2 backbone contains the CMV enhancer, promoter, and first intron to increase expression, the bovine growth hormone polyadenylation sequence, and the kanamycin resistance gene. Where indicated, mice were immunized with the control plasmid VRI012 /3-gal, which encodes /3-galactosidase. 
Data analysis
Minimal estimates of Rev-specific HTLs and proliferating T lymphocytes (PTLs) frequencies were obtained according to the Poisson distribution equation as the slope of a line relating the number of responder cells per microwell (plotted on a linear x axis) and the percentage of microwells that failed to produce IL-2 or proliferate (plotted on a logarithmic y axis). The slope of this regression line was determined by computer, using chisquare minimization analysis as described by Taswell (1981) . This analysis yields the minimal frequency estimate, the 95% confidence interval of the frequency estimate, and a chi-square estunate of probability. Frequency estimates with nonoveriapping 95% confidence intervals are statistically significant.
ELISA for Rev-reactive antibodies
Dilutions of sera (100 pi) were added in tiiplicate to plates coated with recombinant Rev protein (1 /ig/ml). Anti-Rev IgGi monoclonal antibody (Advanced Biotechnologies, Columbia, MD) served as a positive contiol. After a 2-hr incubation at 37°C, plates were washed three times with phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA). One hundred microliters of biotin-conjugated isotype-specific secondary antibodies (1 /u.g/ml) was added and plates were incubated at 37°C for 1 hr. These secondary rat anti-mouse IgM and IgG antibodies were obtained from The Binding Site (San Diego, CA). Plates were washed three times and 100 pi of avidin-peroxidase (1.7 /ag/ml) (Sigma Chemicals) were added. After a 30-min incubation at room temperature, plates were washed three times and 100 pi of ABTS [2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)] substi^ate (Sigma Chemicals) was added to each well. After 30 min, absorbance was determined at 405 nm with an EL 312e microplate reader (Bio-Tek Instruments, Winooski, VT).
Cytokine ELISA Splenocytes obtained from mice immunized with pCMV Rev MlO were stimulated in vitro at a concentration of lOVml with recombinant Rev (0.1 /ig/ml). Supematants (SNs) were harvested at 24 and 72 hr. In some experiments, splenocytes were stimulated with Rev for 5 days, then restimulated with Rev in fresh medium for an additional 72 hr prior to harvesting SN. SN (100 /j,l) was added in triplicate to plates coated with rat anti-mouse interferon ^(IFN-y), IL-4, or IL-10 capture antibodies (5 /Lig/ml; PharMingen, San Diego, CA). Standards were employed by preparing twofold dilutions of murine recombinant IFN-y, IL-4, and IL-10 (PharMingen), with starting concentrations of 25, 2.5, and 10 ng/ml, respectively. After a 1-hr incubation at room temperature, plates were washed three times with 0.05% Tween in PBS. One hundred microliters of rat antimouse secondary biotinylated antibodies (1 /ng/ml; PharMingen) were then added, and plates were incubated at room temperature for 45 min. Plates were then washed three times with 0.05% Tween in PBS, and 100 fil of avidin-peroxidase (Sigma Chemicals) were added. After a 30-min incubation at room temperature, plates were washed three times with 0.05% Tween in PBS, and 100 pi of ABTS substrate (Sigma Chemicals) were then added to each well. After 30 min, absorbance was determined at 405 nm with an EL 312e microplate reader (Bio-Tek Instruments). Sample cytokine concentiations were calculated from a standard curve. The sensitivity of this assay is approximately 300 pg/ml for IFN-y, 100 pg/ml for IL-4, and 150 pg/ml for IL-10.
T cell subset depletion Splenocytes were depleted of CD4"'" or CD8"^ T cells prior to addition to HTL LDA microcultures by complement-mediated cytolysis. Briefly, 1 X 10^ splenocytes/ml were incubated for 1 hronicewitha 1:100 dilution of either anti-CD4(GK1.5) or anti-CD8 (2.43) MAb purified from ascites. Splenocytes were then pelleted, resuspended in Low-Tox-M rabbit complement (Accurate Chemicals, Westbury, NY) diluted 1:10, and incubated for 1 hr at 37°C. Cells were washed three times and resuspended to the appropriate viable cell number for use as responder cells in LDA. Depletion of T cell subsets was verified by flow cytometry (FACScan; Becton Dickinson, Mountain View, CA) using fluorescein isothiocyanate (FITC)-conjugated anti-CD3, -CD4, and -CDS MAbs (PharMingen), which revealed that the targeted subset represented <2% of the residual splenocyte population. T cell subset depletion versus MAb coating was verified by staining with FTTC-conjugated goat anti-rat IgG (Jackson ImmunoResearch Laboratories, Westgrove, PA). To identify immune parameters induced by genetic vaccination with Rev MlO, BALB/c mice were given intramuscular injections with the Rev MlO-encoding plasmid pCMV Rev MlO. Multiple plasmid injections were administered 2 weeks apart in an attempt to induce a vigorous anti-Rev immune response. Splenocytes were harvested 10 days following the last plasmid injection and assessed for responsiveness to recombinant Rev protein in a variety of immunologic assays. Hence, while mice were genetically immunized with Rev MlO, in vitro assays employed Rev as the antigen.
RESULTS
Rev-driven proliferative responses
As shown in Table 1 , splenocytes obtained from mice given three genetic immunizations with pCMV Rev MlO, but not from naive animals, proliferated vigorously in response to recombinant Rev protein. A kinetic study revealed that Rev-driven proliferative responses were detectable following the second intramuscular injection with pCMV Rev MlO, and peaked following the third (data not shown). Dose-response studies (Table 1) demonstrated that in vitro concentrations of recombinant Rev as low as 0.05 /ig/ml were sufficient to drive immune T cell proliferation (simulation index [SI] of 15.2), but did not induce proliferation of naive cells (SI of 1.8). Given these observations, recombinant Rev was used at 0.1 /xg/ml for subsequent in vitro assays.
Rev-reactive helper T lymphocytes responses
The Rev-driven proliferative responses illustiated in Table 1 were detected without the addition of exogenous IL-2 to the culture system. This suggested that Rev-reactive helper T lymphocytes (HTLs) developed after immunization with pCMV Rev MlO, which in tum provided the necessary growth factors for clonal expansion of Rev-reactive T cells. We have previously demonstrated that the presence of IL-2-producing HTLs ''Splenocytes were harvested 6 weeks after the fourth Rev MlO plasmid immunization.
'^As a plasmid control, mice were given four biweekly immunizations with a plasmid encoding /3-galactosidase.
Abbreviations: HTL, Helper T lymphocyte; PTL, proliferating T lymphocyte.
best reflects the ability to mount a deleterious immune response following cardiac transplantation in both mice (Bishop et al, 1992) and humans (DeBruyne et al, 1993 (DeBruyne et al, , 1995 . Hence, we adapted our previously described limiting dilution analysis (LDA) technique (Bishop and Orosz, 1989) to quantify Rev-reactive IL-2-producing HTLs.
Initial studies evaluated the kinetic appearance of Rev-reactive HTLs in the spleens of BALB/c mice following muhiple biweekly injections with pCMV Rev MIO. As shown in Table  2 , Rev-reactive HTLs were rare or not detectable in the spleens of naive mice (1/189,907). However, Rev-reactive HTLs appeared following the second immunization with pCMV Rev MlO and leveled off over the diird and fourth plasmid injections. This induction of Rev-reactive HTLs by pCMV Rev MlO immunization has been observed in more tiian 20 separate experiments, with the frequency of Rev-reactive HTLs ranging from approximately 1/1000-1/15,000. In addition, these Revreactive HTLs persisted in the spleens of mice for at least 6 weeks following the fourth genetic immunization ( Table 2) . As an additional negative control, mice received 4 intt-amuscular injections with a plasmid encoding /3-galactosidase. Immunization with this /3-galactosidase plasmid failed to induce a significant frequency of Rev-reactive HTLs (Table 2 ). Finally, it should be noted that the ability to mount a Rev-reactive HTL response is not unique to the BALB/c mouse, in that C57BL/6 mice immunized with pCMV Rev MlO developed similar HTL responses (data not shown). "BALB/c mice received three to four biweekly intramuscular injections of a plasmid encoding Rev MlO. Ten days after the last immunization, splenocytes were harvested and used as responder cells in an Rev-reactive HTL LDA, or cultured at IX 10* cells/ml in the presence of 0.1 /xg of Rev/ml. Supematants were harvested at 72 hr and IFN-y, IL-4, and IL-10 concentrations were BALB/c splenocytes stimulated witii 1 /xg of ConA/ml for 72 hr.
''ND, Not detectable.
with exogenous IL-2. This PTL LDA is designed to quantify the number of cells capable of proliferating in response to a given antigen when exogenous growth factors are provided. In contrast to HTLs, PTLs were detectable in naive mice (1/20,009), although they increased in number following pCMV Rev MlO immunization. These data suggest tiiat while precursor cells with the potential to respond to Rev are present in naive animals at appreciable frequencies, the limiting factor in mounting an anti-Rev immune response is the IL-2-producing HTL. Further, these data indicate that monitoring HTL frequencies may be used as a sensitive indicator of an Rev MIOinduced response.
Failure to detect additional cytokine production by Rev-reactive T cells
We also assessed the ability of splenocytes obtained from pCMV Rev MlO-immunized mice to produce IFN-y, IL-4, and IL-10. Briefly, immune splenocytes were cultured at 1 X 10*/ml in the presence or absence of recombinant Rev (0.1 /xg/ml). Culture supematants were harvested at 24 and 72 hr and assessed for cytokine content by standard enzyme-linked immunosorbent assay (ELISA). The results of three separate experiments are depicted in Table 3 . Despite the presence of IL-2-producing HTLs, IL-4 and IL-10 were not detectable by ELISA, and IFN-y concentrations were low or not detectable. In additional experiments, immune splenocytes were cultured witii Rev for 5 days, then restimulated with Rev in fresh medium for an additional 72 hr. Cytokine production in these secondary cultures was also not detectable (data not shown). Hence, while pCMV Rev MlO immunization induced IL-2-producing HTLs that were readily detectable by LDA, ELISAs failed to detect the production of additional cytokines by immune T cells.
Phenotype of Rev-reactive helper T lymphocytes
Since IL-2-producing HTLs are CD4+ T cells in many (but not all) systems, we depleted CD4+ or CD8+ cells following the tiiird immunization with pCMV Rev MlO and quantified Rev-reactive HTLs in die selected populations by LDA. As shown in Table 4 , depletion of CD4"'" cells markedly reduced the frequency of Rev-reactive HTLs (1/16,838 -^ 1/52,942), indicating that the majority of HTLs were CD4+. Further, depletion of CD8^ cells increased the frequency of Rev-reactive HTLs (1/5728), likely reflecting the enrichment for CD4+ cells following removal of the CDS"^ population.
TGFpi gene transfer inhibits Rev-reactive helper T lymphocyte development
We next asked if the immune response induced by pCMV Rev MlO immunization could be circumvented by cotransfection with plasmids encoding immunosuppressive agents. To this end, BALB/c mice received three immunizations with either pCMV Rev MlO alone, or pCMV Rev MlO plus a plasmid encoding the active form of human TGF/31. The frequencies of Rev-reactive IL-2-producing HTLs in the spleens of these mice are shown in Table 5 . As described above, immunization with pCMV Rev MlO alone resulted in the development of readily detectable Rev-reactive HTLs (1/11,973). Interestingly, cotransfection with a plasmid encoding the immunosuppressive Since a vigorous HTL response was induced following genetic vaccination with Rev MlO, we asked whether these HTLs provided help for the production of anti-Rev antibodies. An ELISA was employed to detect Rev-reactive IgG and IgM in the sera of mice that had received three injections with pCMV Rev MlO (Fig. 1) . In more than 10 separate experiments. Revreactive IgG antibodies were not detectable by ELISA. While low levels of Rev-reactive IgM antibodies were detectable in the sera of pCMV Rev MlO-immunized mice, similar levels of these IgM antibodies were present in the sera of naive mice (Fig. 1) . One possible explanation for these negative results was that the recombinant Rev protein used to coat the ELISA plate did not adhere effectively to the plate. To test this possibility, varying concentrations of an anti-Rev IgGi MAb were used as the primary antibody in the ELISA. As shown in Fig. 1 , reactivity with the anti-Rev MAb was readily demonstrable, verifying the utility of this Rev ELISA in detecting anti-Rev antibodies. Finally, to demonstrate that BALB/c mice could mount a detectable anti-Rev IgG response, we immunized animals intraperitoneally with recombinant Rev in Freund's complete ad- 
DISCUSSION
The efficacy of in vivo gene ti-ansfer stiategies is limited by the relative immunogenicity of both the transgene product and the vector employed to facilitate ti-ansfection. Gene tiansfer-induced immune responses may eliminate transfected cells, thereby limiting duration of transgene expression. Further, local inflammation induced by the transgene product and/or vector within transfected tissues may compromise normal tissue function, thereby exacerbating, rather than alleviating, the original disease process. The current study focused on the immune response induced by in vivo inttoduction of the anti-HIV gene. Rev MlO. Transfection of human T cells with Rev MlO renders these cells resistant to HIV replication in vitro (Bevec et al, 1992; Malim et al, 1992; Woffendin et al, 1994) , and cells that have been retrovhally ttansduced with Rev MlO may persist for extended periods when reintroduced into HIV-infected individuals in vivo (Ranga et al, 1998) . Nonetiieless, the effects of the immune response on the long-term survival and function of Rev MlO-ttansduced cells have not been established, and may negatively influence the efficacy of this anti-HIV gene therapy. Indeed, Riddell et al. (1996) reported that T cells that expressed a foreign selection marker were eliminated by the immune response to the ttansgene product when these cells were inttoduced into HIV-infected individuals. To date, the potential immunogenicity of Rev MlO gene transfer has not been rigorously explored. Hence, mice were deliberately immunized by repeated inttamuscular administrations of plasmid encoding Rev MlO in an attempt to define immune parameters that could be mobilized by Rev MlO gene transfer. Studies that have assessed the cellular immune responses to Rev are limited. Blazevic etal. (1995) attempted to identify immunogenic regions of Rev by evaluating the ability of polyclonal T cell lines obtained from HIV-infected individuals to incorporate deoxyuridine when stimulated with synthetic Rev peptides. Several peptides approximately 15 amino acids in length had stimulatory activity for polyclonal T cell lines obtained from some, but not all, individuals. Weak cytotoxic T lymphocyte (CTL) responses were also detectable when autologous Epstein-Barr virus (EBV)-transformed B cells were pulsed with these peptides and used as CTL target cells. However, responses were quite variable, and the majority of individuals failed to respond to any ofthe 13 peptides tested (Blazevic et al, 1995) . Similar to our study. Shiver et al. (1995) reported that vaccination of mice with a Rev-encoding plasmid generated cells that proliferated in response to recombinant Rev protein in vitro. Further, Shiver et al. stated that IFN-y, but not IL-4, was produced when splenocytes from plasmid-vaccinated mice were stimulated with Rev in vitro. However, the amount of IFN-y produced by these cells was not presented. In the current study, we assessed Rev-induced production of IFN-y, IL-4, and IL-10 by splenocytes obtained from mice following multiple immunizations with Rev MlO-encoding plasmids (Table  3) . IL-4 and IL-10 were not detectable by ELISA in the supernatants of these Rev-stimulated splenocytes, and IFN-y production was lunited or not detectable. It should be noted that plasmid pCMV Rev MlO used in our study contains a kanamycin resistance gene, while the Rev-encoding plasmid employed by Shiver et al. was derived from pUC19, which contains an ampicillin selection marker. Sato et al. (1996) reported that the unmethylated CpG motifs present in the ampicillin, but not the kanamycin, resistance gene promote the development of IFN-y-producing helper T cell type 1 (Thi) cells following DNA vaccination. Hence, differences in the Rev-induced WNy response observed in our study and that of Shiver et al. may reflect differences in the CpG content ofthe plasmids employed. Altematively, differences may be attributed in part to the use of plasmids encoding wild-type Rev versus Rev MlO. However, it should be noted that Rev MlO differs from wild-type Rev by only two amino acid substitutions (Malim et al, 1991) . The impact of this difference on the immune response to Rev has not been defined.
Like Shiver et al. (1995) , we found that Rev MlO gene ttansfer induced a vigorous proliferative response to Rev (Table 1) . This response was observed when splenocytes from immunized, but not naive, mice were cultured at high cell concenttation (IX 10^/ml) in the presence of recombinant Rev. Proliferation in these bulk cultures suggested that cells capable of producing IL-2 or other T cells growth factors were induced by Rev MlO genetic immunization. In addition, PTL LDA revealed that cells with the potential to proliferate to Rev were readily detectable in both immunized and naive mice (Table 2) . Since the PTL LDA employed in this study is supplemented with exogenous IL-2, this observation suggested that a limiting factor in the ability of naive cells to respond to Rev was a requirement for Rev-reactive IL-2 producing cells. Indeed, we (Bishop et al, 1992; DeBruyne et al, 1993 DeBruyne et al, , 1995 and others (Theobald et al, 1992) have reported that the presence of IL-2-producing HTL reflects the ability of an individual to mount a clinically significant immune response to alloantigens. As predicted, Revreactive HTLs were not present in naive mice, but appeared following two genetic immunizations with pCMV Rev MlO ( Table  2) .
The observation that Rev-reactive HTLs were CD4''- (Table  4) is of interest. Rev is a DNA-binding protein and therefore is not actively secreted. Hence, the Rev MlO transgene product should not be readily available for presentation to CD4-'-cells via the class II antigen presentation pathway (reviewed by Braciale and Braciale, 1991) . Given the cellular localization of Rev, one might predict that gene transfer of Rev MlO would preferentially stimulate CDS'"-T cells via class I antigen presentation. However, we were unable to detect Rev-reactive CDS"^ CTLs, using established LDA techniques (Orosz et al, 1989; Bishop et al, 1992; Nabel et al, 1996) with Rev MlO-ttansduced RENCA cells serving as CTL targets (data not shown). Nonetheless, CD4-'-HTLs were reproducibly induced by pCMV Rev MlO immunization, indicating that the ttansgene product entered the class II antigen presentation pathway. However, genetic vaccination did not stimulate an anti-Rev antibody response (Fig. 1) , indicating that the transgene product was not available for recognition by B cells. Shiver et al. (1995) also reported that genetic immunization with Rev failed to elicit an antibody response. It should be noted that Rev may induce an antibody response in both HIV-infected individuals (Devash et al, 1990) and in mice immunized with Rev protein (Fig. 1  and VoU et al, 1990) . Hence, the mode of delivery of Rev ap-pears to influence the scope of the response that is elicited. Others have reported that the nature of a ttansgene-induced response may be influenced by the route of DNA administration and by the tissue and cell types that are transfected. For example, Raz et al. (1994) reported an antibody, rather than a cellular response, was induced when the transgene was introduced intradermally, as opposed to intramuscularly. Similarly, Feltquate et al. (1997) reported that a Thi response is preferentially induced by a transgene product when plasmids are inttoduced in saline. In contrast, gene gun delivery of the DNA preferentially induces a Th2 response to the ttansgene product. Aspects of the immune response induced by the introduction of Rev MlO-transduced hematopoietic cells in humans have not been defined, and are currentiy being explored in our laboratory.
Several immunosuppressive strategies have been explored as a means to inhibit the immune response to both transgene products and viral vectors. These include inhibitors of cytokine synthesis such as cyclosporin A (Fang et al, 1995) , blockade of costimulatory pathways with either CTLA4Ig or anti-CD40 ligand MAb , and ttansient depletion of CD4+ T cells (DeMatteo et al, 1996) . In addition, coadministtation of genes encoding immunosuppressive agents shows promise as an altemate approach to control gene transfer-induced responses. Examples of this strategy include the ttansfer of genes encoding immunosuppressive proteins of the E3 region of adenovirus (Lee et al, 1995; llan et ai, 1997) , IL-1 receptor antagonist (McCoy et ai, 1995) , and the EBV product viral IL-10 (Qin et al, 1997) . Our observation that cotransfer of a plasmid encoding the active form of human TGF/31 ablates the HTL response induced by Rev MlO genetic vaccination (Table 5 ) further supports the utility of "genetic immunosuppression" in the management of ttansgene-induced immune responses. TGF/31 is a pleiotrophic cytokine that mediates multiple antiinflammatory activities (Wahl, 1994) , including inhibition of Thi responses (Schmitt et al, 1994) , E-selectin expression by endothelial cells (Gamble et ai, 1993) , and CTL development (Inge et al, 1992) . However, excess production or systemic administration of TGF/31 has been associated with unresolved inflammation and fibrosis (Border and Ruoslahti, 1992; Wahl, 1994) . It should be noted that no adverse effects were observed when mice received intramuscular injections of plasmid encoding TGF/31 in this study. Parameters assessed included physical activity, weight loss, coat condition, and splenomegaly. Hence, local delivery of TGF/31 via plasmid inoculation provided the desired immunosuppressive effect without overt toxicity.
To our knowledge, this study represents the first to quantify IL-2-producing HTLs as an indicator of the immune response induced by a plasmid encoding Rev MlO in vivo. We suggest that similar HTL responses may be mounted to other transgene products, and that LDA may prove useful in monitoring the evolution of gene transfer-induced immune responsiveness in the setting of replacement gene therapy and of genetic vaccination. Finally, data from this study support the feasibility of combining genes that encode immunosuppressive cytokines with the transgene of interest as a modification aimed at inhibiting the development of transgene-neutralizing immune responses.
